<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD001168-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD001168-sec-0050"></div> <div class="table" id="CD001168-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids compared to placebo for treating oral lichen planus</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Corticosteroids compared to placebo for treating symptomatic, biopsy‐confirmed oral lichen planus</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with oral lichen planus </p> <p><b>Setting:</b> university dental clinics </p> <p><b>Intervention:</b> topical corticosteroids </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Certainty of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with corticosteroids</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pain resolution**</b> </p> <p>measured via VAS (1‐10cm) and 5‐grade score</p> <p>Follow‐up: 8‐9 weeks</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>306 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>584 per 1000<br> (330 to 1000) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.91</b> </p> <p>(1.08 to 3.36)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br><b>Low</b><sup>a,c</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 RCT evaluated clobetasol propionate and the other flucinonide.</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical resolution***</b> </p> <p>measured via</p> <p>Thongparsom and 5‐grade score</p> <p>Follow‐up: 8‐9 weeks</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>50 per 1000<sup>b</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>300 per 1000</p> <p>(38 to 2379)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 6.00</b> </p> <p>(0.76 to 47.58)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>a,d</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 RCT evaluated clobetasol propionate and the other flucinonide.</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects****</b> </p> <p>Follow‐up: 3‐9 weeks</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>89 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>132 per 1000<br> (43 to 405) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.48</b> </p> <p>(0.48 to 4.56)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88<br> (3 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>a,d</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RCTs evaluated clobetasol propionate, flucinonide (no adverse effects noted) and triamcinolone acetonide. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Subjective assessment by participants at the end of treatment</p> <p>***Assessment by clinicians at the end of treatment</p> <p>****Reported by participants throughout the study</p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias (one study judged at unclear risk).<br><sup>b</sup>There was zero risk in control group so we assumed a rate of 5%.<br><sup>c</sup>Downgraded one level due to imprecision (few participants and large CI).<br><sup>d</sup>Downgraded two levels due to serious imprecision (few participants and large CI that includes possibility of either corticosteroid or placebo being superior). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD001168-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span> <span class="table-title">Corticosteroids versus calcineurin inhibitors for treating oral lichen planus</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="left" valign="top" colspan="8" rowspan="1" bgcolor="#ffffff"> <p><b>Corticosteroids compared to calcineurin inhibitors for treating symptomatic, biopsy‐confirmed oral lichen planus</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="8" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with oral lichen planus </p> <p><b>Setting:</b> university dental clinics </p> <p><b>Intervention:</b> topical corticosteroids </p> <p><b>Comparison:</b> topical calcineurin inhibitors </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="2" class="table-tint table-highlight"> <p><b>Treatment comparison</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>№ of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Certainty of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with calcineurin inhibitors</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Risk with corticosteroids</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Pain resolution**</b> </p> <p>measured via VAS and 4‐grade scale</p> <p>Follow‐up: 3‐8 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>clobetasol vs ciclosporin</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>200 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>422 per 1000<br> (152 to 1000) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 2.11</b> </p> <p>(0.76 to 5.86)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>39<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>a</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>clobetasol vs tacrolimus</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>440 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>198 per 1000<br> (106 to 387) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.45</b> </p> <p>(0.24 to 0.88)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>b</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>triamcinolone vs tacrolimus</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data for this outcome</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Clinical resolution***</b> </p> <p>measured via Thongprasom and 4‐grade scale</p> <p>Follow‐up: 3‐8 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>clobestol vs ciclosporin</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>150 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>474 per 1000<br> (150 to 1000) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 3.16</b> </p> <p>(1.00 to 9.93)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>39<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>c</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>clobetasol vs tacrolimus</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>654 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>399 per 1000<br> (248 to 647) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.61</b> </p> <p>(0.38 to 0.99)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>d</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>triamcinolone vs tacrolimus</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>467 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>401 per 1000<br> (257 to 630) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.86</b> </p> <p>(0.55 to 1.35)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>e</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Adverse effects****</b> </p> <p>Follow‐up: 3‐8 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>clobetasol vs ciclosporin</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>50 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>316 per 1000<br> (42 to 1000) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 6.32</b> </p> <p>(0.84 to 47.69)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>39<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>a</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>clobetasol vs tacrolimus</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>180 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 per 1000<br> (0 to 149) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.05</b> </p> <p>(0.00 to 0.83)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br><b>Very low</b><sup>f</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>triamcinolone vs tacrolimus</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>516 per 1000</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>243 per 1000<br> (114 to 511) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.47</b> </p> <p>(0.22 to 0.99)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>58<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br><b>Low</b><sup>g</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="8" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Subjective assessment by participants at the end of treatment</p> <p>***Assessment by clinicians at the end of treatment</p> <p>**** Reported by participants throughout the duration of the study</p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="8" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels as very small single study at unclear risk of bias, with large CI that includes the possibility of either intervention being superior.<br><sup>b</sup>Downgraded three levels as small number of participants, with one study at unclear risk of bias, and very high heterogeneity.<br><sup>c</sup>Downgraded three levels as very small single study at unclear risk of bias, with large CI that included the possibility that there is no difference between the interventions.<br><sup>d</sup>Downgraded three levels as small number of participants in two studies at unclear risk of bias, and very high heterogeneity.<br><sup>e</sup>Downgraded three levels as small number of participants in two studies at unclear risk of bias, and very high heterogeneity, with large CI that included the possibility of either intervention being superior.<br><sup>f</sup>Downgraded three levels as small number of participants and events, both studies at unclear risk of bias and large CI including no difference between the interventions.<br><sup>g</sup>Downgraded two levels as small number of participants and wide CI, and one study at unclear risk of bias. </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
